Development of therapeutic HPV vaccines

被引：70

作者：

Trimble, Cornelia L. ^{[1
]}

Frazer, Ion H. ^{[2
]}

机构：

[1] Johns Hopkins Univ Hosp, Baltimore, MD 21205 USA

[2] Diamantina Inst Canc Immunol & Metab Med, Woolloongabba, Qld, Australia

来源：

LANCET ONCOLOGY | 2009年 / 10卷 / 10期

基金：

英国医学研究理事会;

关键词：

CERVICAL INTRAEPITHELIAL NEOPLASIA; HUMAN-PAPILLOMAVIRUS INFECTION; MEDIATED IMMUNE-RESPONSES; CYTOTOXIC T-LYMPHOCYTES; VIRUS-LIKE PARTICLES; PHASE-I TRIAL; NATURAL-HISTORY; ANTIBODY-RESPONSES; CELL RESPONSES; PHYSICAL STATE;

D O I：

10.1016/S1470-2045(09)70227-X

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

At least 15% of human malignant diseases are attributable to the consequences of persistent viral or bacterial infection. Chronic infection with oncogenic human papillomavirus (HPV) types is a necessary, but insufficient, cause in the development of more cancers than any other virus. Currently available prophylactic vaccines have no therapeutic effect for established infection or for disease. Early disease is characterised. by tissue sequestration. However, because a proportion of intraepithelial HPV-associated disease undergoes immune-mediated regression, the development of immunotherapeutic strategies is an opportunity to determine proof-of-principle for therapeutic vaccines. In this Review, we discuss recent progress in this field and priorities for future clinical investigations.

引用

页码：975 / 980

页数：6

共 72 条

[1]

Baldwin PJ, 2003, CLIN CANCER RES, V9, P5205

[2]

Bontkes HJ, 2000, INT J CANCER, V88, P92, DOI 10.1002/1097-0215(20001001)88:1<92::AID-IJC15>3.0.CO

[3]

2-E

[4] A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer [J].